Bausch Health Companies Q3 2024 Earnings Report

Bausch Health Companies EPS Results

• Actual EPS: $1.12
• Consensus EPS: $1.02
• Beat/Miss: Beat by +$0.10
• One Year Ago EPS: $1.03

Bausch Health Companies Revenue Results

• Actual Revenue: $2.51 billion
• Expected Revenue: $2.42 billion
• Beat/Miss: Beat by +$88.62 million
• YoY Revenue Growth: +12.20%

Bausch Health Companies Announcement Details

• Quarter: Q3 2024
• Date: 10/30/2024
• Time: After Market Closes

Bausch Health Companies (NYSE:BHC) operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.